Maija Hollmén

Company: Faron Pharmaceuticals

Job title: Chief Scientific Officer

Bio:

Maija Hollmén, PhD is the CSO at Faron and an adjunct professor of tumor immunology, group leader, and Academy Research Fellow at the MediCity Research Laboratory, University of Turku, Finland. Her research focuses on targeting immunosuppressive macrophages via the scavenger receptor Clever-1 to drive tumor inflammation resolution and develop companion diagnostics and therapeutics. She combines in vivo tumor models with advanced immunological assays and human cancer samples to accelerate bench-to-bedside progress

Seminars:

Comparing & Contrasting the Different Myeloid Pathways for Functional Reprogramming to Identify Which Pathways are Better Targets 9:00 am

A comprehensive deep dive into the key molecular pathways, cell-surface receptors, intracellular regulators, and emerging targets involved in the reprogramming of myeloid cells. Rank different pathways by therapeutic potential, feasibility and safety, to ultimately improve and better identify functional reprogramming strategies. Review the major myeloid-targeted strategies being pursued to reprogram immune-suppressive cells (especially M2-like TAMs)…Read more

day: Pre-Conference Workshop Day

Who to Treat, When to Treat? Biomarkers & Disease Stage in Myeloid Therapeutics 12:00 pm

The importance of disease staging and how improper patient stratification can affect the efficacy of certain drugs Understanding why some respond and some don’t, correlating TME features with clinical outcomes Single-cell and spatial insights into late-stage vs. baseline tumors Myeloid content and architecture as predictors of checkpoint responseRead more

day: Conference Day One